ArticleScientific reports2019
Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Identification of microbial markers associated with lung cancer based on multi-cohort 16 s rRNA analyses: A systematic review and meta-analysis.Cancer medicine · 2023Pooled it
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.iScience · 2026Review
- Dynamic balance of the lung microbiome in health and respiratory diseases.Chinese medical journal · 2026Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Lung microbiota analysis in early-stage lung adenocarcinoma.Microbiology spectrum · 2026Article
- Intratumoral microbiota and metabolites: dual roles in cancer progression and therapeutic opportunities.Cell communication and signaling : CCS · 2026Review
- The oral-lung axis in lung cancer: microbial translocation, immune reprogramming, and clinical implications.Frontiers in immunology · 2026Review
- Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.Nature communications · 2025Article
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- The microbiome in cancer.iMeta · 2025Review
- The role of oral microbiota in lung carcinogenesis through the oral-lung axis: a comprehensive review of mechanisms and therapeutic potential.Discover oncology · 2025Review
- Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features.BMC microbiology · 2025Article
- Exploring the metabolomics and metagenomics of chronic obstructive pulmonary disease (COPD) and lung cancer: unraveling the complex interplay.Journal of thoracic disease · 2025Review
- The tumor microbiome in cancer progression: mechanisms and therapeutic potential.Molecular cancer · 2025Review
- DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis.Infectious agents and cancer · 2025Article
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025Review
- Classification of NSCLC subtypes using lung microbiome from resected tissue based on machine learning methods.NPJ systems biology and applications · 2025Article
- The microbiome and lung cancer: microbial effects on host immune responses and treatment outcomes.Frontiers in microbiomes · 2025Review
- Integrative multi-omics analysis of the microbiome and metabolome in bronchoalveolar lavage fluid from patients with early-stage lung cancer.Frontiers in cellular and infection microbiology · 2025Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lung is a complex ecosystem of host cells and microbes often disrupted in pathological conditions. Although bacteria have been hypothesized as agents of carcinogenesis, little is known about microbiota profile of the most prevalent cancer subtypes: adenocarcinoma (ADC) and squamous cell carcinoma (SCC). To characterize lung cancer (LC) microbiota a first a screening was performed through a pooled sequencing approach of 16S ribosomal RNA gene (V3-V6) using a total of 103 bronchoalveaolar lavage fluid samples. Then, identified taxa were used to inspect 1009 cases from The Cancer Genome Atlas and to annotate tumor unmapped RNAseq reads. Microbial diversity was analyzed per cancer subtype, history of cigarette smoking and airflow obstruction, among other clinical data. We show that LC microbiota is enriched in Proteobacteria and more diverse in SCC than ADC, particularly in males and heavier smokers. High frequencies of Proteobacteria were found to discriminate a major cluster, further subdivided into well-defined communities' associated with either ADC or SCC. Here, a SCC subcluster differing from other cases by a worse survival was correlated with several Enterobacteriaceae. Overall, this study provides first evidence for a correlation between lung microbiota and cancer subtype and for its influence on patient life expectancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.